---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050060"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:01:40.970580+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aditxt reiterates Sept 2025 close target for Evofem deal; Evofem had $19.5M revenue, first ex-US deal signed

## Summary
- Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.
- Evofem generated $19.5M net revenue last year; has two FDA-approved products (Phexxi, Solosec) and signed first ex-US deal with Pharma 1 in Middle East.
- New manufacturer Lee Pharma committed to lowering Evofem's COGS by over 50% to mitigate tariff volatility and support European expansion.
- Pearsanta's endometriosis/ovarian cancer diagnostic platform expected near revenue in Q4 2025; Adimune autoimmune program targets regulatory filing.

## SEC filing metadata
- accession: 0001213900-25-050060
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/0001213900-25-050060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/ea0244325-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050060
- JSON: https://secwatch.observer/filing/0001213900-25-050060.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.